{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:55:31Z","timestamp":1783605331409,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s12149-021-01634-3","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T17:25:55Z","timestamp":1622136355000},"page":"1004-1014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of different examination conditions on image quality and quantitative value of amyloid positron emission tomography using 18F-flutemetamol"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3339-4742","authenticated-orcid":false,"given":"Tamaki","family":"Otani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kou","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Otomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamato","family":"Kunikane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Azane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"key":"1634_CR1","first-page":"1358","volume":"40","author":"MT Hays","year":"1999","unstructured":"Hays MT, Segall GM. A mathematical model for the distribution of fluorodeoxyglucose in humans. J Nucl Med. 1999;40:1358\u201366.","journal-title":"J Nucl Med"},{"key":"1634_CR2","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/jon.12643","volume":"29","author":"Y Chiba","year":"2019","unstructured":"Chiba Y, Fujishiro H, Iseki E, Kasanuki K, Sato K. The cingulate island sign on FDG-PET vs IMP-SPECT to assess mild cognitive impairment in Alzheimer\u2019s disease vs. dementia with Lewy bodies. J Neuroimaging. 2019;29:712\u201320.","journal-title":"J Neuroimaging"},{"key":"1634_CR3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1212\/WNL.0000000000001877","volume":"85","author":"E Liu","year":"2015","unstructured":"Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, et al. Amyloid-\u03b2 11 C-PiB-PET imaging results from 2 randomized Bapineuzumab phase 3 AD trials. Neurology. 2015;85:692\u2013700.","journal-title":"Neurology"},{"key":"1634_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.nucmedbio.2010.02.003","volume":"37","author":"KJ Lin","year":"2010","unstructured":"Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent\u2014a pilot study. Nucl Med Biol. 2010;37:497\u2013508.","journal-title":"Nucl Med Biol"},{"key":"1634_CR5","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.2967\/jnumed.115.158774","volume":"56","author":"F Carbonell","year":"2015","unstructured":"Carbonell F, Zijdenbos AP, Charil A, Grand\u2019Maison M, Bedell BJ. Alzheimer\u2019s disease neuroimaging initiative. Optimal target region for subject classification on the basis of amyloid PET images. J Nucl Med. 2015;56:1351\u20138.","journal-title":"J Nucl Med"},{"key":"1634_CR6","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","volume":"50","author":"N Nelissen","year":"2009","unstructured":"Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50:1251\u20139.","journal-title":"J Nucl Med"},{"key":"1634_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O\u2019Keefe G, et al. Imaging of amyloid beta in Alzheimer\u2019s disease with 18F-BAY94- 9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129\u201335.","journal-title":"Lancet Neurol"},{"key":"1634_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jalz.2010.03.003","volume":"6","author":"WJ Jagust","year":"2010","unstructured":"Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer\u2019s disease neuroimaging initiative positron emission tomography core. Alzheimers Dement. 2010;6:221\u20139.","journal-title":"Alzheimers Dement"},{"key":"1634_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jalz.2015.05.001","volume":"11","author":"WJ Jagust","year":"2015","unstructured":"Jagust WJ, Landau SM, Koeppe RA, Reiman EM, Chen K, Mathis CA, et al. The Alzheimer\u2019s Disease Neuroimaging Initiative positron emission tomography core: 2015. Alzheimers Dement. 2015;11:757\u201371.","journal-title":"Alzheimers Dement"},{"key":"1634_CR10","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.jalz.2018.03.009","volume":"14","author":"T Iwatsubo","year":"2018","unstructured":"Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, et al. Japanese and North American Alzheimer\u2019s Disease Neuroimaging Initiative studies: harmonization for international trials. Alzheimers Dement. 2018;14:1077\u201387.","journal-title":"Alzheimers Dement"},{"key":"1634_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s12149-015-1024-0","volume":"30","author":"G Akamatsu","year":"2016","unstructured":"Akamatsu G, Ikari Y, Nishio T, Nishida H, Ohnishi A, Aita K, et al. Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging. Ann Nucl Med. 2016;30:18\u201328.","journal-title":"Ann Nucl Med"},{"key":"1634_CR12","unstructured":"Standard PET imaging protocols and phantom test procedures and criteria: executive summary. Japanese Society of Nuclear Medicine website. http:\/\/jsnm.org\/wp_jsnm\/wp-content\/uploads\/2020\/10\/StandardProtocolforAmyloid_20201005.pdf.(Accessed 25 Nov 2020)"},{"key":"1634_CR13","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s00259-016-3591-2","volume":"44","author":"T Yamane","year":"2017","unstructured":"Yamane T, Ishii K, Sakata M, Ikari Y, Nishio T, Ishii K, et al. Inter- rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer\u2019s Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging. 2017;44:850\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1634_CR14","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2967\/jnumed.114.142109","volume":"55","author":"L Thurfjell","year":"2014","unstructured":"Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med. 2014;55:1623\u20138.","journal-title":"J Nucl Med"},{"key":"1634_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.nicl.2015.10.007","volume":"9","author":"JM Mountz","year":"2015","unstructured":"Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, et al. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer\u2019s subjects. Neuroimage Clin. 2015;9:592\u20138.","journal-title":"Neuroimage Clin"},{"key":"1634_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00259-013-2564-y","volume":"41","author":"S Hatashita","year":"2014","unstructured":"Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2014;41:290\u2013300.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1634_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2967\/jnumed.118.211532","volume":"60","author":"LE Collij","year":"2019","unstructured":"Collij LE, Konijnenberg E, Reimand J, Kate MT, Braber AD, Alves IL, et al. Assessing amyloid pathology in cognitively normal subjects using 18F-flutemetamol PET: comparing visual reads and quantitative methods. J Nucl Med. 2019;60:541\u20137.","journal-title":"J Nucl Med"},{"key":"1634_CR18","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s12149-019-01397-y","volume":"33","author":"M Kameyama","year":"2019","unstructured":"Kameyama M, Ishibash K, Wagatsuma K, Toyohara J, Ishii K. A pitfall of white matter reference regions used in [18F] florbetapir PET: a consideration of kinetics. Ann Nucl Med. 2019;33:848\u201354.","journal-title":"Ann Nucl Med"},{"key":"1634_CR19","doi-asserted-by":"publisher","first-page":"578753","DOI":"10.3389\/fneur.2020.578753","volume":"11","author":"H Matsuda","year":"2021","unstructured":"Matsuda H, Ito K, Ishii K, Shimosegawa E, Okazawa H, Mishina M, et al. Quantitative evaluation of 18F-Flutemetamol PET in patients with cognitive impairment and suspected Alzheimer\u2019s disease: a multicenter study. Front Neurol. 2021;11:578753.","journal-title":"Front Neurol"},{"key":"1634_CR20","unstructured":"The imaging acquisition guidelines of the 18F-flutemetamol (Vizamyl\u00ae) package insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203137s008lbl.pdf. (Accessed 08 Mar 2021)."},{"key":"1634_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/brb3.146","volume":"3","author":"E Imabayashi","year":"2013","unstructured":"Imabayashi E, Matsuda H, Tabira T, Arima K, Araki N, Ishii K, et al. Comparison between brain CT and MRI for voxel-based morphometry of Alzheimer\u2019s disease. Brain Behav. 2013;3:487\u201393.","journal-title":"Brain Behav"},{"key":"1634_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2967\/jnmt.114.140665","volume":"42","author":"G Akamatsu","year":"2014","unstructured":"Akamatsu G, Uba K, Taniguchi T, Mitsumoto K, Narisue A, Tsutsui Y, et al. Impact of time-of-flight PET\/CT with a large axial field of view for reducing whole-body acquisition time. J Nucl Med Technol. 2014;42:101\u20134.","journal-title":"J Nucl Med Technol"},{"key":"1634_CR23","first-page":"2019","volume":"35","author":"H Lida","year":"1994","unstructured":"Lida H, Itoh H, Nakazawa M, Hatazawa J, Nishimura H, Onishi Y, et al. Quantitative mapping of regional cerebral blood flow using iodine-123-IMP and SPECT. J Nucl Med. 1994;35:2019\u201330.","journal-title":"J Nucl Med"},{"key":"1634_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00259-012-2268-8","volume":"40","author":"S Tiepolt","year":"2013","unstructured":"Tiepolt S, Barthel H, Butzke D, Hesse S, Patt M, Gertz HJ, et al. Influence of scan duration on the accuracy of \u03b2-amyloid PET with florbetaben in patients with Alzheimer\u2019s disease and healthy volunteers. Eur J Nucl Med Mol Imaging. 2013;40:238\u201344.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01634-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-021-01634-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01634-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T14:46:10Z","timestamp":1628174770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-021-01634-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1007\/s12149-021-01634-3","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No potential conflicts of interest were disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}